Pre-Exposure Prophylaxis Barriers, Facilitators and Unmet Need Among Rural People Who Inject Drugs: A Qualitative Examination of Syringe Service Program Client Perspectives

Hilary L Surratt, Hannah J Yeager, Akosua Adu, Evelyn A González, Elizabeth O Nelson, Tamara Walker, Hilary L Surratt, Hannah J Yeager, Akosua Adu, Evelyn A González, Elizabeth O Nelson, Tamara Walker

Abstract

Background: People who inject drugs (PWID) are at high risk for HIV infection, yet in rural areas PWID are understudied with respect to prevention strategies. Kentucky is notable for heavy rural HIV burden and increasing rates of new HIV diagnoses attributable to injection drug use. Despite high need and the strong evidence for Pre-Exposure Prophylaxis (PrEP) as a gold-standard biomedical HIV prevention tool, scale up has been limited among PWID in Kentucky and elsewhere. This paper explores individual, environmental, and structural barriers and facilitators of PrEP care from the perspective of PWID in rural Kentucky.

Methods: Data are drawn from an ongoing NIH-funded study designed to adapt and integrate a PrEP initiation intervention for high-risk PWID at point of care in two rural syringe service programs (SSPs) in southeastern Kentucky. As part of this initiative, a qualitative study guided by PRISM (Practical, Robust, Implementation, and Sustainability Model) was undertaken to gather SSP client perspectives on intervention needs related to PrEP, competing needs related to substance use disorder, as well as tangible supports for and barriers to PrEP uptake. Recruitment and interviews were conducted during September-November 2021 with 26 SSP clients, 13 from each of the two SSP sites. A semi-structured guide explored injection behaviors, SSP use, knowledge of PrEP, perceived barriers to PrEP, as well as aspects of the risk environment (e.g., housing instability, community stigma) that may impact PrEP uptake. Interviews were digitally recorded, transcribed verbatim and verified by project staff. A detailed coding scheme was developed and applied by independent coders using NVivo. Coded transcripts were synthesized to identify salient themes in the data using the principles of thematic analysis All study procedures were approved by the University IRB.

Results: Participants were 96% white, 42% female, with a median age of 41 years (range 21-62); all reported injection use within the past month. Overall, we found low PrEP awareness among this sample, yet interest in PrEP was high, with several indicating PrEP is urgently needed. Clients reported overwhelmingly positive experiences at the SSPs, considering them trusted and safe locations to receive health services, and were enthusiastic about the integration of co-located PrEP services. Lack of basic HIV and PrEP knowledge and health literacy were in evidence, which contributed to common misperceptions about personal risk for HIV. Situational risks related to substance use disorder, particularly in the context of withdrawal symptoms and craving, often lead to heightened HIV injection and sexual risk behaviors. Stigma related to substance use and HIV arose as a concern for PrEP uptake, with several participants reflecting that privacy issues would impact their preferences for education, prescribing and monitoring of PrEP. Noted tangible barriers included inconsistent access to phone service and transportation. Primary supports included high levels of insurance coverage, consistent pharmacy access, and histories with successful medication management for other health conditions.

Conclusions: Drawing on the critical perspectives of people with substance use disorder, our findings provide important and actionable information on individual and environmental barriers and facilitators of PrEP uptake among rural PWID at high risk for HIV infection. These data will drive the adaptation and implementation of a client-centered approach to integrated PrEP care within rurally located SSP settings to address unmet needs for PrEP care.

Keywords: HIV prevention; PrEP; implementation science; people who inject drugs; rural; stigma.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Surratt, Yeager, Adu, González, Nelson and Walker.

References

    1. Fauci AS, Lane HC. Four decades of HIV/AIDS — much accomplished, much to do. N Engl J Med. (2020) 383:1–4. 10.1056/NEJMp1916753
    1. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. . Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. (2017) 5:e1192–207. 10.1016/S2214-109X(17)30375-3
    1. Samoff E, Mobley V, Hudgins M, Cope AB, Adams ND, Caputo CR, et al. . HIV outbreak control with effective access to care and harm reduction in North Carolina, 2017–2018. Am J Public Health. (2020) 110:394–400. 10.2105/AJPH.2019.305490
    1. West Virginia Office of Epidemiology Prevention Services . Increase in HIV: Outbreak of Human Immunodeficiency Virus (HIV) linked to injection drug use. (2020). Available online at: (accessed January 9, 2022).
    1. Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. . Community outbreak of HIV infection linked to injection drug use of oxymorphone–Indiana, 2015. Morb Mortal Wkly Rep. (2015) 64:443–4. Available online at :
    1. Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR, Shields J, et al. . HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N Engl J Med. (2016) 375:229–39. 10.1056/NEJMoa1515195
    1. Pitasi MA, Delaney KP, Brooks JT, DiNenno EA, Johnson SD, Prejean J. HIV testing in 50 local jurisdictions accounting for the majority of new HIV diagnoses and seven states with disproportionate occurrence of HIV in rural areas, 2016–2017. Morb Mortal Wkly Rep. (2019) 68:561–7. 10.15585/mmwr.mm6825a2
    1. Paquette CE, Pollini RA. Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: a systematic review. Drug Alcohol Depend. (2018) 188:239–50. 10.1016/j.drugalcdep.2018.03.049
    1. Neaigus A, Zhao M, Gyarmathy VA, Cisek L, Friedman SR, Baxter RC. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health. (2008) 85:309–22. 10.1007/s11524-008-9271-1
    1. Vogt RL, Breda MC, Des Jarlais DC, Gates S, Whiticar P. Hawaii's statewide syringe exchange program. Am J Public Health. (1998) 88:1403–4.
    1. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Beatrice S, Milliken J, et al. . HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. (2005) 95:1439–44. 10.2105/AJPH.2003.036517
    1. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, et al. . A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. Aids. (2007) 21:1923–32. 10.1097/QAD.0b013e32823f9066
    1. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. (2008) 16:CD004145. 10.1002/14651858.CD004145.pub3
    1. Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, et al. . HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr. (2010) 55:65–72. 10.1097/QAI.0b013e3181d916db
    1. World Health Organization . Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment, and Care for Key Populations. Geneva: WHO; (2014).
    1. World Health Organization . Guideline on When to Start Antiretroviral Therapy and on Pre-Exposure Prophylaxis for HIV September. Geneva: WHO; (2015).
    1. Mayer KH, Hosek S, Cohen S, Liu A J, Pickett Warren M, et al. . Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc. (2015) 18(4 Suppl. 3):19980. 10.7448/IAS.18.4.19980
    1. Kennedy C, Fonner V. Pre-exposure prophylaxis for people who inject drugs: a systematic review. In: Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations−2016 Update. Annex 2. Geneva: World Health Organization; (2016).
    1. Centers for Disease Control Prevention . Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through March 2021; and preexposure prophylaxis (PrEP) data reported through December 2020. Available online at: (accessed December 27, 2021).
    1. Sherman SG, Schneider KE, Park JN, Allen ST, Hunt D, Chaulk CP, et al. . PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. (2019) 195:148–55. 10.1016/j.drugalcdep.2018.08.014
    1. Allen ST, O'Rourke A, White RH, Smith KC, Weir B, Lucas GM, et al. . Barriers and facilitators to PrEP use among people who inject drugs in rural appalachia: a qualitative study. AIDS Behav. (2019) 24:1942–50. 10.1007/s10461-019-02767-3
    1. Bazzi AR, Biancarelli DL, Childs E, Drainoni ML, Edeza A, Salhaney P, et al. . Limited knowledge and mixed interest in pre-exposure prophylaxis for HIV prevention among people who inject drugs. AIDS Patient Care STDS. (2018) 32:529–37. 10.1089/apc.2018.0126
    1. Biello KB, Bazzi AR, Mimiaga MJ, Biancarelli DL, Edeza A, Salhaney P, et al. . Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduct J. (2018) 15:55. 10.1186/s12954-018-0263-5
    1. Bolinski R, Ellis K, Zahnd WE, Walters S, McLuckie C, Schneider J, et al. . Social norms associated with nonmedical opioid use in rural communities: a systematic review. Transl Behav Med. (2019) 9:1224–32. 10.1093/tbm/ibz129
    1. Schafer KR, Albrecht H, Dillingham R, Hogg RS, Jaworsky D, Kasper K, et al. . The Continuum of HIV Care in Rural Communities in the United States and Canada: what is known and future research directions. J. Acquir. Immune Defic. Syndr. (2017) 75:35–44. 10.1097/QAI.0000000000001329
    1. Hoth AB, Shafer C, Dillon DB, Mayer R, Walton G, Ohl ME. Iowa TelePrEP: a public-health-partnered telehealth model for human immunodeficiency virus preexposure prophylaxis delivery in a rural state. Sex Transm Dis. (2019) 46:507–. 10.1097/OLQ.0000000000001017
    1. Schranz AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C. Curr HIV/AIDS Rep. (2018) 15:245–54. 10.1007/s11904-018-0393-0
    1. Hubach RD, Currin JM, Sanders CA, Durham AR, Kavanaugh KE, Wheeler DL, et al. . Barriers to access and adoption of pre-exposure prophylaxis for the prevention of HIV among men who have sex with men (MSM) in a relatively rural state. AIDS Educ Prev. (2017) 29:315–29. 10.1521/aeap.2017.29.4.315
    1. Crowley JS, Bland SE. Achieving sufficient scale up of PrEP use is critical to ending the HIV epidemic. In: Big Ideas: Issue Brief. O'Neill Institute for National and Global Health Law. Washington, DC: Georgetown University; (2019).
    1. Zhang HL, Rhea SK, Hurt CB, Mobley VL, Swygard H, Seña AC, et al. . HIV preexposure prophylaxis implementation at local health departments: a statewide assessment of activities and barriers. J Acquir Immune Defic Syndr. (2018) 77:72–7. 10.1097/QAI.0000000000001546
    1. Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. . The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. (2018) 28:841–9. 10.1016/j.annepidem.2018.06.005
    1. Siegler AJ, Bratcher A, Weiss KM. Geographic access to preexposure prophylaxis clinics among men who have sex with men in the United States American. J Public Health. (2019) 109:1216–23. 10.2105/AJPH.2019.305172
    1. Feldstein AC, Glasgow RE. A practical, robust implementation and sustainability model (PRISM) for integrating research findings into practice. Jt Comm J Qual Patient Saf . (2008) 34:228–43. 10.1016/S1553-7250(08)34030-6
    1. Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. . HIV and risk environment for injecting drug users: the past, present, and future. Lancet. (2010) 376:268–84. 10.1016/S0140-6736(10)60743-X
    1. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. (2009) 20:193–201. 10.1016/j.drugpo.2008.10.003
    1. Marshall BDL, Kerr T, Shoveller JA, Montaner JSG, Wood E. Structural Factors Associated with an Increased Risk of HIV and sexually transmitted infection transmission among street-involved youth. BMC Public Health. (2009) 9:7. 10.1186/1471-2458-9-7
    1. Surratt HL, Otachi JK, McLouth CJ, Vundi N. Healthcare stigma and HIV risk among rural people who inject drugs. Drug Alcohol Depend. (2021) 226:108878. 10.1016/j.drugalcdep.2021.108878
    1. Cloud DH, Ibragimov U, Prood N, Young AM, Cooper HLF. Rural risk environments for hepatitis c among young adults in Appalachian Kentucky. Int J Drug Policy. (2019) 72:47–54. 10.1016/j.drugpo.2019.05.006
    1. Surratt HL, Otachi JK, Williams T, Gulley J, Lockard AS, Rains R. Motivation to change and treatment participation among syringe service program utilizers in rural Kentucky. J Rural Health. (2020) 36:224–33. 10.1111/jrh.12388
    1. Surratt HL, Cowley AM, Gulley J, Lockard S, Otachi J, Rains R, et al. . Syringe service program use among people who inject drugs in appalachian Kentucky. Am J Public Health. (2020) 110:34–6. 10.2105/AJPH.2019.305333
    1. Surratt HL, Staton CM, Vundi N. Expanding access to HIV testing and diagnosis among people who inject drugs in high HIV burden areas of the rural United States. In: Poster Presented at the 23rd International AIDS Conference (2020).
    1. Pagkas-Bather J, Jaramillo J, Henry J, Grandberry V, Ramirez LF, Cervantes L, et al. . What's PrEP?: peer navigator acceptability among minority MSM in Washington. BMC Public Health. (2020) 20:248. 10.1186/s12889-020-8325-5
    1. Edhlund B, Mcdougall A. NVivo 11 Essentials: (2016).
    1. Roberts K, Dowell A, NieJB. Attempting rigour and replicability in thematic analysis of qualitative research data; a case study of codebook development. BMC Med Res Methodol. (2020) 19:66. 10.1186/s12874-019-0707-y
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qualit Res Psychol. (2006) 3:77–101. 10.1191/1478088706qp063oa
    1. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC Health Serv Res. (2017) 17:1–3. 10.1186/s12913-017-2031-8
    1. Baker P, Beletsky L, Avalos L, Venegas C, Rivera C, Strathdee SA, et al. . Policing practices and risk of HIV infection among people who inject drugs. Epidemiol Rev. (2020) 42:27–40. 10.1093/epirev/mxaa010
    1. Strathdee S, Beletsky L, Kerr T. HIV, drugs and the legal environment. Int J Drug Policy. (2015) 26:S27–32. 10.1016/j.drugpo.2014.09.001
    1. Furukawa NW, Weimer M, Willenburg KS, Kilkenny ME, Atkins AD, Paul McClung R, et al. . Expansion of preexposure prophylaxis capacity in response to an HIV outbreak among people who inject drugs—Cabell County, West Virginia, 2019. Public Health Rep. (2022) 137:25–31. 10.1177/0033354921994202
    1. Friedman SR, Pouget ER, Sandoval M, Rossi D, Mateu-Gelabert P, Nikolopoulos GK, et al. . Interpersonal attacks on the dignity of members of HIV key populations: a descriptive and exploratory study. AIDS Behav. (2017) 21:2561–78. 10.1007/s10461-016-1578-4
    1. Ellis K, Walters S, Friedman SR, Ouellet LJ, Ezell J, Rosentel K, et al. . Breaching trust: A qualitative study of healthcare experiences of people who use drugs in a rural setting. Front Sociol. (2020) 5:593925. 10.3389/fsoc.2020.593925
    1. Walters SM, Frank D, Van Ham B, Jaiswal J, Muncan B, Earnshaw VA, et al. . PrEP care continuum engagement among persons who inject drugs: rural and urban differences in stigma and social infrastructure. AIDS Behav. (2022) 26:1308–20. 10.1007/s10461-021-03488-2
    1. Benbow S, Forchuk C, Berman H, Gorlick C, Ward-Griffin C. Spaces of exclusion: safety, stigma, and surveillance of mothers experiencing homelessness. Can J Nurs Res. (2019) 51:202–13. 10.1177/0844562119859138
    1. Sullivan PS, Mena L, Elopre L, Siegler AJ. Implementation strategies to increase PrEP Uptake in the South. Curr HIV/AIDS Rep. (2019) 16:259–69. 10.1007/s11904-019-00447-4
    1. White W, Cloud W. Recovery capital: a primer for addictions professionals. Counselor. (2008) 9:22–7. Available online at:
    1. Wood TJ, Koester KA, Christopoulos KA, Sauceda JA, Neilands TB, Johnson MO. If someone cares about you, you are more apt to come around: improving HIV care engagement by strengthening the patient-provider relationship. Patient Prefer Adherence. (2018) 12:919–27. 10.2147/PPA.S157003
    1. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. (2004) 39: 1005–26. 10.1111/j.1475-6773.2004.00269.x
    1. Torrens M, Soyemi T, Bowman D, Schatz E. Beyond clinical outcomes: The social and healthcare system implications of hepatitis C treatment. BMC Infect Dis. (2020) 20:702. 10.1186/s12879-020-05426-4

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다